Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
40.20B
Market cap40.20B
Price-Earnings ratio
69.74
Price-Earnings ratio69.74
Dividend yield
Dividend yield
Average volume
1.39M
Average volume1.39M
High today
$304.20
High today$304.20
Low today
$292.24
Low today$292.24
Open price
$295.18
Open price$295.18
Volume
1.41M
Volume1.41M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$273.11
52 Week low$273.11

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $304.20. The company's market cap stands at 40.2B, with a P/E ratio of 69.74.

On 2026-07-01, Alnylam Pharmaceuticals(ALNY) stock traded between a low of $292.24 and a high of $304.20. Shares are currently priced at $304.20, which is +4.1% above the low and 0.0% below the high.

Alnylam Pharmaceuticals(ALNY) shares are trading with a volume of 1.41M, against a daily average of 1.39M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

ALNY News

Investing.com 17h
Canaccord reiterates Alnylam stock Buy rating after RNAi event - Investing.com

...

Canaccord reiterates Alnylam stock Buy rating after RNAi event - Investing.com
TipRanks 2d
Alnylam price target lowered to $470 from $510 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Alnylam (ALNY) to $470 from $510 and keeps a Buy rating on the shares. The firm reduced its near-term estimat...

TipRanks 5d
Alnylam: Buy Rating Reaffirmed as Differentiated RNAi Pipeline and Upcoming Catalysts Support Unchanged $550 Price Target

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Alnylam Pharma, retaining the price target of $550.00. Unlock powerful investing tools and...

Analyst ratings

71%

of 31 ratings
Buy
71%
Hold
29%
Sell
0%

More ALNY News

TipRanks 6d
Komodo expands strategic partnership with Alnylam

Komodo Health announced an expanded strategic partnership with Alnylam (ALNY) Pharmaceuticals. Built on the Healthcare Map, Marmot, Komodo’s analytics AI platfo...

Simply Wall St 7d
AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam

In recent days, GENESIS Pharma announced it has expanded its commercial partnership with Alnylam Pharmaceuticals to include Sweden, Finland, Denmark, and Norway...

AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.